All In Biotech

NDA 022341 · Novo Nordisk INC

Victoza

Liraglutide · Subcutaneous · GLP-1 Receptor Agonist

Novel

Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jan 25, 2010

Approved uses

7

Original approval plus efficacy supplements

Registered trials

434

113 Phase 3, 21 recruiting

FAERS reports

42,518

20,310 serious, 1,689 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • Liraglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of liraglutide and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using...

What it is approved for

From the label in effect Jan 30, 2026.

Liraglutide is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use : Liraglutide contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) Limitations of Use : • Coadministration with other liraglutide-containing products is not recommended.

Mechanism: Liraglutide is an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells. Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VICTOZA · LIRAGLUTIDE 18MG/3ML (6MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP1

Clinical trials

Interventional ClinicalTrials.gov studies with "Liraglutide" as an intervention, any sponsor and status, largest first.

All 434 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea6,032
  • blood glucose increased3,867
  • diarrhoea2,986
  • vomiting2,924
  • pancreatitis2,105
  • weight decreased2,042
  • decreased appetite1,856
  • headache1,716
  • off label use1,584
  • fatigue1,361
  • dizziness1,301
  • constipation1,297

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20083
20092
20102,707
20115,445
20122,909
20131,584
20141,936
20154,834
20163,571
20172,596
20184,068
20192,527
20202,243
20211,752
20221,313
20231,146
20241,055
20251,426
20261,398

Recalls

1 FDA enforcement reports for this application.

  • Mar 22, 2021 · Class II · Terminated

    Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Shortages

FDA's drug shortage list.

  • Current · updated Sep 22, 2026

    Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20). Distributed by Teva

  • Current · updated Sep 22, 2026

    Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13). Delay in shipping of the drug

  • Current · updated Sep 22, 2026

    Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22). Distributed by Teva

  • Current · updated Sep 22, 2026

    Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12). Delay in shipping of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,035 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.